{
    "clinical_study": {
        "@rank": "136004", 
        "arm_group": [
            {
                "arm_group_label": "Ceftaroline fosamil", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "IV Ceftriaxone and Vancomycin", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study of safety and effectiveness of ceftaroline fosamil in children with\n      Complicated Community-acquired Pneumonia receiving antibiotic therapy in the hospital."
        }, 
        "brief_title": "Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Infections", 
            "Pneumonia"
        ], 
        "condition_browse": {
            "mesh_term": "Pneumonia"
        }, 
        "detailed_description": {
            "textblock": "To evaluate safety, effectiveness, pharmacokinetics and tolerance of ceftaroline fosamil in\n      pediatric subjects ages 2 months to < 18 years who are initially hospitalized with\n      Complicated Community Acquired Bacterial Pneumonia (CABP) at high risk of infection due to\n      methicillin-resistant Staphylococcus aureus (MRSA)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Presence of CABP warranting 3 days of initial hospitalization\n\n          -  Confirmed presence of indicators of complicated CABP\n\n        Exclusion Criteria:\n\n          -  Hypersensitivity or allergic reaction to vancomycin or any \u03b2-lactam   antimicrobial\n\n          -  Confirmed or suspected infection with a pathogen known to be resistant to IV study\n             drugs or known infection at baseline with a sole atypical organism\n\n          -  Confirmed or suspected respiratory tract infection attributable to sources other than\n             community acquired bacterial pneumonia\n\n          -  Non-infectious causes of pulmonary infiltrates"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669980", 
            "org_study_id": "P903-24"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ceftaroline fosamil", 
                "description": "Subjects \u2265 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (\u00b1 10) minutes q8h (\u00b1 1 hour)\nSubjects < 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (\u00b1 10) minutes q8h (\u00b1 1 hour)\nOptional Oral Switch:\nPO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h\nPO clindamycin 13 mg/kg/dose\nPO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h", 
                "intervention_name": "Ceftaroline fosamil", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Teflaro", 
                    "PPI-0903", 
                    "TAK-599", 
                    "TAK599", 
                    "PPI0903"
                ]
            }, 
            {
                "arm_group_label": "IV Ceftriaxone and Vancomycin", 
                "description": "IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (\u00b1 2 hours) infused over 30 (\u00b1 10) minutes AND\nIV vancomycin 15 mg/kg every 6 hours (q6h) (\u00b1 1 hour) infused over at least 60 minutes.\nOptional Oral Switch:\nPO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h\nPO clindamycin 13 mg/kg/dose\nPO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h", 
                "intervention_name": "IV Ceftriaxone and Vancomycin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amoxicillin", 
                "Ceftriaxone", 
                "Clindamycin", 
                "Vancomycin", 
                "Amoxicillin-Potassium Clavulanate Combination", 
                "Clavulanic Acid"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Infections", 
            "Pediatrics", 
            "Teflaro", 
            "Ceftriaxone", 
            "cephalosporin", 
            "Vancomycin", 
            "Clindamycin", 
            "Amoxicillin Clavulanate", 
            "Linezolid", 
            "MRSA", 
            "pneumonia"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "link": {
            "description": "Sponsor Homepage", 
            "url": "http://www.cerexa.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Long Beach", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oakland", 
                        "country": "United States", 
                        "state": "California"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orange County", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toledo", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morgantown", 
                        "country": "United States", 
                        "state": "West Virginia"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buenos Aires", 
                        "country": "Argentina"
                    }, 
                    "name": "Investigative Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tbilisi", 
                        "country": "Georgia"
                    }, 
                    "name": "Investigational Site 1"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tbilisi", 
                        "country": "Georgia"
                    }, 
                    "name": "Investigational Site 2"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tbilisi", 
                        "country": "Georgia"
                    }, 
                    "name": "Investigational Site 3"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Donetsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ivano-Frankivsk", 
                        "country": "Ukraine"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kryvyi Rih", 
                        "country": "Ukraine"
                    }, 
                    "name": "Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyiv", 
                        "country": "Ukraine"
                    }, 
                    "name": "Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Argentina", 
                "Georgia", 
                "Ukraine"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia (CABP)", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board", 
                "Romania: National Agency for Medicines and Medical Devices", 
                "Romania: Ethics Committee", 
                "Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluate the safety and tolerability of IV administered ceftaroline fosamil in children with complicated CABP. Summaries of patient AEs, SAEs, deaths, discontinuations due to AEs, laboratory evaluations (hematology studies, comprehensive and metabolic panel), and vital signs will be provided for each treatment group.", 
            "measure": "Evaluate the safety and tolerability of ceftaroline versus ceftriaxone plus vancomycin in pediatric subjects ages 2 months to < 18 years with complicated community-acquired bacterial pneumonia (CABP)", 
            "safety_issue": "Yes", 
            "time_frame": "between 1 and 57 days"
        }, 
        "removed_countries": {
            "country": "Romania"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669980"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluate the efficacy of ceftaroline versus ceftriaxone plus vancomycin in pediatric subjects with complicated CABP at high risk of infection due to methicillin-resistant Staphylococcus aureus (MRSA) by assessing clinical stability of the subject at study day 4 and clinical outcome at End of IV, End of Treatment and Test of Cure.", 
                "measure": "To evaluate the efficacy of ceftaroline versus ceftriaxone plus vancomycin in pediatric subjects with complicated CABP at high risk of infection due to methicillin-resistant Staphylococcus aureus (MRSA).", 
                "safety_issue": "No", 
                "time_frame": "between 4 and 57 days"
            }, 
            {
                "description": "Analyze concentrations of ceftaroline, ceftaroline fosamil (prodrug), and ceftaroline M-1 (inactive metabolite) in plasma, and, if available, in cerebrospinal fluid (CSF, if collected as part of standard of care)", 
                "measure": "Evaluate the pharmacokinetics of ceftaroline in pediatric subjects with complicated CABP at high risk of infection due to methicillin-resistant Staphylococcus aureus (MRSA)", 
                "safety_issue": "No", 
                "time_frame": "between  4 and 57 days"
            }
        ], 
        "source": "Cerexa, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cerexa, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}